Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

On Tuesday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.92 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.18. The stock opened at $60.14 and touched a ...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive ...

On Friday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.29 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.09. The stock opened at $60 and ...

Catalent (CTLT) sells Somerset, NJ facility to Ardena. Corporate headquarters to shift to new location post-transition.

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...